Aditxt (ADTX) said Monday that its Pearsanta unit has begun enrolling patients in a prospective clinical study evaluating the Mitomic Endometriosis Test, a blood-based diagnostic tool for endometriosis.
The study, which will enroll up to 1,000 participants, is intended to evaluate the clinical performance of the Mitomic Endometriosis Test compared with laparoscopic diagnosis, Aditxt said.
Shares of Aditxt were up more than 6% in recent premarket activity Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments